Frontiers in Immunology · 2023 · 16 citations · 21 references
MedicineCancer BiologyOncologyMolecular OncologyTumor ImmunologyTumor MicroenvironmentCancer BiomarkersCancer GenomicsCancer ImmunotherapyCancer Molecular PathologyCancer TranscriptomicsImmuno-oncology BiomarkersCancer Genomics DatabasesCircadian Rhythm Gene ExpressionClock-controlled GenesImmune Biomarkers In CancerImmunosuppressive MicroenvironmentPrognostic Biomarker DiscoveryTumor Immune Microenvironment ProfilingTumor Microenvironment Biomarkers
Background: Aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2) belongs to the b HLH- PAS domain transcription factor family and is one of the key clock genes that control the circadian rhythm. ARNTL2 plays an important role in human biological functions. However, its role in various tumors, especially in the tumor immune microenvironment (TIME) and immunotherapy, remains unclear. Methods: experiments to investigate the involvement of ARNTL2 expression in cancer prognosis and immune response. Results: ARNTL2 displayed abnormal expression within most malignant tumors, and is significantly associated with poorer survival and pathologic staging. Through gene-set enrichment analysis (GSEA) and gene-set variation analysis (GSVA), we found that ARNTL2 not only regulates cell cycle-related functions to promote cell proliferation but also regulates autoimmunity-related functions of the innate and adaptive immune systems, and other immune-related signaling pathways. In addition, ARNTL2 overexpression contributes to an immunosuppressive tumor microenvironment that plays a key role in immunosuppression-related features, such as the expression of immunosuppression-related genes and pathways and the number of immunosuppressive-infiltrating cells, including regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs). The group of patients with low ARNTL2 expression who received immune checkpoint inhibitors (ICI) therapy had better response rates and longer survival when compared to those with high ARNTL2 expression. Conclusion: The findings of this study suggest that ARNTL2 is a potential human oncogene that plays an important role in tumorigenesis and cancer immunity. Elevated ARNTL2 expression indicates an immunosuppressive tumor microenvironment. Targeting ARNTL2 in combination with ICI therapy could bring more significant therapeutic benefits to patients with cancer. Our study sheds light on the remarkable potential of ARNTL2 in tumor immunity and provides a novel perspective for anti-tumor strategies.
21
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text
The Immune Landscape of Cancer
Vésteinn Thórsson, David L. Gibbs, Scott D. Brown et al. · Immunity · 2018 · 6.2K citations · Full text
Medicine, Immunology, Oncology +17
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth, Michael D. McLellan, Fabio Vandin et al. · Nature · 2013 · 4.5K citations · Full text
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.4K citations · Full text
Medicine, Cancer Biology, Oncology +14
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Bo Li, Eric A. Severson, Jean‐Christophe Pignon et al. · Genome biology · 2016 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17